Results 31 to 40 of about 35,587 (246)

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. [PDF]

PLoS ONE, 2017
Mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene were recently discovered in vast majority of World Health Organization (WHO) grade II/III gliomas.
Huixia Zhu, Ye Zhang, Jianfeng Chen, Jiangdong Qiu, Keting Huang, Mindan Wu, Chunlin Xia   +6 more
doaj   +1 more source

Immunohistochemical Expression of IDH1, ATRX, Ki67, GFAP, and Prognosis in Indonesian Glioma Patients

International Journal of General Medicine, 2023
Dody Priambada,1 Muhamad Thohar Arifin,1 Abdi Saputro,1 Azka Muzakka,1 Vega Karlowee,2 Udadi Sadhana,2 Yuriz Bakhtiar,1 Krisna Tsaniadi Prihastomo,1 Ajid Risdianto,1 Happy Kurnia Brotoarianto,1 Erie Andar,1 Zainal Muttaqin1 1Department of Neurosurgery ...
Priambada D, Thohar Arifin M, Saputro A, Muzakka A, Karlowee V, Sadhana U, Bakhtiar Y, Prihastomo KT, Risdianto A, Brotoarianto HK, Andar E, Muttaqin Z   +11 more
doaj  

The diagnostic value of lower glucose consumption for IDH1 mutated gliomas on FDG-PET

BMC Cancer, 2021
Background Non-invasive diagnosis of IDH1 mutation for gliomas has great clinical significance, and PET has natural advantage to detect metabolism, as IDH mutated gliomas share lower glucose consumption. Methods Clinical data of patients with gliomas and
Feng-Min Liu, Yu-fei Gao, Yanyan Kong, Yihui Guan, Jinsen Zhang, Shuai-Hong Li, Dan Ye, Wenyu Wen, Chuantao Zuo, Wei Hua   +9 more
doaj   +1 more source

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes

Hematology, 2023
Objective IDH1/2 mutations, intervening in epigenetic procedures, are frequently encountered in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Vasiliki Papadopoulou, Jacqueline Schoumans, Valentin Basset, Françoise Solly, Jérôme Pasquier, Sabine Blum, Olivier Spertini   +6 more
doaj   +1 more source

Favorable role of IDH1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

Future Science OA, 2021
Aim: The implications of molecular biomarkers IDH1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Materials & methods: Glioma cases were analyzed for IDH1/2 mutations and MGMT promoter methylation
Arshad A Pandith, Iqbal Qasim, Shahid M Baba, Aabid Koul, Wani Zahoor, Dil Afroze, Adil Lateef, Usma Manzoor, Ina A Bhat, Dheera Sanadhya, Abdul R Bhat, Altaf U Ramzan, Fozia Mohammad, Iqra Anwar   +13 more
doaj   +1 more source

TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms

Turkish Journal of Hematology, 2017
We aimed to determine the genotype distribution, allele frequency, and prognostic impact of IDH1/2, TET2, and ASXL1 single nucleotide polymorphisms (SNPs) in myeloproliferative neoplasms (MPNs).
Nur Soyer, Burçin Tezcanlı Kaymaz, Melda Cömert Özkan, Çağdaş Aktan, Ali Şahin Küçükaslan, Fahri Şahin, Buket Kosova, Güray Saydam   +7 more
doaj   +1 more source

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Diagnostics, 2021
Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively.
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes   +10 more
doaj   +1 more source

Significance and Impact of Changing WHO Classification Systems on Glial Tumors with Special Reference to IDH1 Mutation in Resource-Limited Setups

Asian Pacific Journal of Cancer Biology, 2023
Objectives: To reclassify glial neoplasms according to the 2021 WHO CNS tumor classification and to study the expression pattern of Isocitrate dehydrogenase 1 (IDH1) mutation by immunohistochemistry(IHC) and to categorize these tumors on the basis of ...
Divya Singh, Vatsala Misra, Kachnar Varma   +2 more
doaj   +1 more source

Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date

Cancer Management and Research, 2023
Pedro Luiz Serrano Uson Junior,1– 3 Mitesh J Borad1 1Mayo Clinic Cancer Center, Mayo Clinic, Phoenix, AZ, USA; 2HCOR, Hospital do Coração, Sao Paulo, Brazil; 3Center for Personalized Medicine, Hospital Israelita Albert Einstein, Sao Paulo ...
Uson Junior PLS, Borad MJ
doaj  

IDH1 and IDH2 mutations in lung adenocarcinomas: Evidences of subclonal evolution

Cancer Medicine, 2020
Background Selective IDH1 and IDH2 inhibitors have been approved for targeted therapy of acute myeloid leukemia. Clinical trials for solid tumors with IDH1 and IDH2 (IDH1/2) mutations are ongoing.
Erika F. Rodriguez, Federico De Marchi, Parvez M. Lokhandwala, Deborah Belchis, Rena Xian, Christopher D. Gocke, James R. Eshleman, Peter Illei, Ming‐Tseh Li   +8 more
doaj   +1 more source